IN8BIO INC (INAB)

US45674E1091 - Common Stock

1.39  -0.01 (-0.71%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

IN8BIO INC

NASDAQ:INAB (6/12/2024, 11:08:23 AM)

1.39

-0.01 (-0.71%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-26.7%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap61.33M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

INAB Daily chart

Company Profile

IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company is headquartered in New York City, New York and currently employs 26 full-time employees. The company went IPO on 2020-11-12. The company is focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead product candidates are in Phase 1 clinical trials: INB-200, for the treatment of patients with newly diagnosed glioblastoma (GBM), and INB-100, for the treatment of patients with hematologic malignancies that are undergoing hematopoietic stem cell transplantation. The company is also focused on patient enrollment in the Company-sponsored Phase 2 clinical trial of INB-400 in which autologous genetically modified gamma-delta T cells will be assessed in newly diagnosed GBM patients. Its DeltEx platform has yielded a portfolio of preclinical programs, including INB-300 and INB-500, focused on addressing GBM and other solid tumor types.

Company Info

IN8BIO INC

Empire State Building, 350 5Th Avenue, Suite 5330

New York City NEW YORK

P: 16466006438

CEO: William Ho

Employees: 26

Website: https://www.in8bio.com

INAB News

News Image9 days ago - IN8bio, IncIN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting...

News Image19 days ago - IN8bio, IncIN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024...

News Image20 days ago - IN8bio, IncIN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting

IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting...

News Imagea month ago - IN8bio, IncIN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress

IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress...

News Imagea month ago - InvestorPlaceINAB Stock Earnings: IN8bio Misses EPS for Q1 2024

INAB stock results show that IN8bio missed analyst estimates for earnings per share the first quarter of 2024.

News Imagea month ago - BusinessInsiderINAB Stock Earnings: IN8bio Misses EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips IN8bio (NASDAQ:INAB) just reported results for the first quarter of 2024.IN8bio...

INAB Twits

Here you can normally see the latest stock twits on INAB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example